Gara Jalqabaatti › Myeloma Baay’ee › Alabama › Birmingham
Qorannoo klinikaalii Myeloma Baay’ee Birmingham, AL keessatti
Qorannoo 18 Myeloma Baay’ee f Birmingham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Alabama At Birmingham Hospital, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Alabama Oncology, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama Birmingham, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Namoota walitti qabaa jiraSadarkaa 3
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Namoota walitti qabaa jira
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- UAB Comprehensive Cancer Center, Birmingham
Qorannoo Myeloma Baay’ee magaalota biroo keessatti
- New York City, NYQorannoo 60
- Boston, MAQorannoo 42
- Atlanta, GAQorannoo 41
- Houston, TXQorannoo 38
- Durham, NCQorannoo 37
- Nashville, TNQorannoo 32
- Denver, COQorannoo 27
- Rochester, MNQorannoo 24
- St. Louis, MOQorannoo 24
- Columbus, OHQorannoo 24
- Baldwin Park, CAQorannoo 23
- Chicago, ILQorannoo 22
Qorannoo biroo Birmingham keessatti
- Saree (Gosoota Hunda)Qorannoo 30
- Saree OljooQorannoo 24
- ObesityQorannoo 23
- Kansarii OvariiQorannoo 23
- Kansara Qara'a Non-Small CellQorannoo 22
- Leukemia Myeloidii HamaaQorannoo 21
- COPDQorannoo 17
- Dhibee Onneessaa fi DhiigaQorannoo 17
- Baayyee UlfaataaQorannoo 16
- Kansa EndometiriyaaliiQorannoo 16
- Sukkaraa Gosa 2Qorannoo 16
- Faayibrosisis KistiiqiiQorannoo 16
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.